Avid Bioservices Inc (CDMO)

[sunstar]

“Targeting phosphatidylserine in combination with adoptive T cell transfer eliminates advanced tumors without off-target toxicities in a melanoma preclinical model”

*Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory, New York, New York, USA

*Weill Cornell Medical and Graduate Schools, New York, New York, USA
?*Peregrine Pharmaceuticals, Inc., Tustin, CA

Peregrine’s Bavituximab, anti-PS pre-clinical molecule has demonstrated the ability to combine with CAR T and eliminate off-target toxicities.

“...a third of the patients in some trials given CAR T cells have developed life- threatening fevers and inflammation.”

CAR T companies should be on our radar. Bavituximab may offer a +50% boost for CAR T safety/efficacy.


http://www.peregrineinc.com/images/stories/pdfs/aacr2017hirschhorn.pdf

https://finance.yahoo.com/news/safety-switches-may-redeem-potent-050000072.html

IMO

sunstar